Drug Trial Radar · NCT07635914
A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension
Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
382
Planned (sponsor's estimate)
Start
May 31, 2026
Primary completion
Dec 28, 2029
Study completion May 31, 2030
Sponsor
- Lead sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of aprocitentan tablets(SYH9108) in patients with treatment-resistant hypertension (rHTN)
Conditions
- Resistant Hypertension
Interventions
Aprocitentan tablets(SYH9108)Drug
For oral administration
PlaceboDrug
For oral administration. The placebo is identical to aprocitentan tablets(SYH9108) in appearance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Sitting Systolic Blood Pressure (SiSBP) after 8 weeks of treatment.Time frame: Baseline and week 8
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.